Georgina Venetia LongAO is an Australian oncologist, clinical trialist and translational researcher, and works in drug therapy development. Long was the first woman and first Australian to be named president of the US-based Society for Melanoma Research.[1]
Long had five siblings and grew up in Sydney's inner west. She also lived in Europe and America as a child.[3] She completed high school at Santa Sabina College in 1988.[4]
Long began studying a combined degree of science and law at the University of Sydney, but gave up law and graduated with a double major in pure maths and chemistry in 1993, before completing a PhD in organic chemistry, also at Sydney University, in 1996.[5][6] She was a postdoctoral researcher at the Scripps Research Institute in California as a Fulbright Fellow, before returning to Australia to undertake her medical degree, graduating with an MBBS in 2001.[5][6]
Career
Long is a medical oncologist specialising in melanoma. She has led numerous clinical trials,[7][8] focusing on targeted therapies and immuno-oncology in melanoma.[9] She is the chief investigator on research into the molecular biology of melanoma.[10]
Long is Director of the Melanoma Institute Australia. Together with pathologist Richard Scolyer, they have been part of a team pioneering the use of immunotherapy treatment for melanoma, which Long then adapted for brain cancer when Scolyer was diagnosed with it in June 2023.[11][12] He was the first brain cancer patient in the world to have pre-surgery combination immunotherapy.[13][14]
↑ Blank, Christian U.; Lucas, Minke W.; Scolyer, Richard A.; van de Wiel, Bart A.; Menzies, Alexander M.; Lopez-Yurda, Marta; Hoeijmakers, Lotte L.; Saw, Robyn P. M.; Lijnsvelt, Judith M.; Maher, Nigel G.; Pulleman, Saskia M.; Gonzalez, Maria; Torres Acosta, Alejandro; van Houdt, Winan J.; Lo, Serigne N. (7 November 2024). "Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma". The New England Journal of Medicine. 391 (18): 1696–1708. doi:10.1056/NEJMoa2402604. ISSN1533-4406. PMID38828984.
↑ Ertl, Carolin; Ruf, Theresa; Mentzer, Dirk; Kong, Mingzi; Kramer, Rafaela; Bergwelt-Baildon, Michael von; Subklewe, Marion; Tomsitz, Dirk; Ascierto, Paolo A.; Dummer, Reinhard; Gogas, Helen; Lebbé, Celeste; Long, Georgina V.; McArthur, Grant; Neilan, Tomas G. (March 2024). "The side effect registry immuno-oncology (SERIO) - A tool for systematic analysis of immunotherapy-induced side effects". European Journal of Cancer. 199 113505. doi:10.1016/j.ejca.2023.113505. ISSN1879-0852. PMID38262306.
This page is based on this Wikipedia article Text is available under the CC BY-SA 4.0 license; additional terms may apply. Images, videos and audio are available under their respective licenses.
